Cyclacel Pharmaceuticals (CYCC) Expected to Announce Quarterly Earnings on Tuesday

Cyclacel Pharmaceuticals (NASDAQ:CYCC) will likely be issuing its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Cyclacel Pharmaceuticals Stock Performance

Shares of NASDAQ:CYCC opened at $0.30 on Monday. The stock has a market capitalization of $1.87 million, a price-to-earnings ratio of -0.03 and a beta of 0.28. Cyclacel Pharmaceuticals has a 1-year low of $0.29 and a 1-year high of $4.00. The company has a 50 day moving average price of $0.35 and a 200 day moving average price of $0.57.

Insider Activity at Cyclacel Pharmaceuticals

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of the stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total value of $5,838,864.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 23.97% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals in a research report on Saturday. They issued a “sell” rating for the company.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.